Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: J&J ups guidance; Gilead’s acquisition strategies; Bayer breakup rumors; Biogen’s Alzheimer’s results; and an interview with Lilly’s blood test pioneer.
Scrip - July 21, 2026

CorTec’s BCI Shows Early Promise In Stroke Rehab With 8 to 12 Point FMA-UE Gains
CorTec’s implantable BCI system has shown early safety and functional gains in three stroke patients, with Fugl-Meyer (FMA-UE) upper extremity improving by 8-12 points. Rivals Neurolutions, Mobia Medical and Enspire leverage EEG, VNS and DBS technologies respectively also use FMA-UE as benchmark.
Medtech Insight - July 21, 2026

IFF Trims Business Focus While SuanNutra Adds Scale In Supplement Ingredients Portfolio Deal
Deal expected to close during 2026 includes IFF’s portfolio of botanical extracts, vitamins and minerals and food enhancement activities, including its natural colors and antioxidants and some flavor activities in Peru. Financial terms weren’t disclosed.
HBW Insight - July 20, 2026

‘World’s Best-Smelling Sunscreen’ Claim Puffery Until Paired With Reviews – NAD
The National Advertising Division reviewed a challenge brought by Nivea marketer Beiersdorf against Vacation for ‘World’s Best-Smelling Sunscreen’ claim.
HBW Insight - July 20, 2026

EU Regulators Flag Probiotics And Ginseng Supplements As Possible ‘Emerging Risks’
Six food supplement ingredients, including ginseng and the probiotic bifidobacterium, have been flagged as possible emerging risks by EU regulators, raising the prospect of future sales restrictions across the bloc.
HBW Insight - July 20, 2026

No-Regrets Move: PwC Makes The Case For Building Consumer Health Innovation Around Wellness Goals
Consumers are managing their health continuously and across more product categories than ever. PwC's Anthony Bruce says this presents an opportunity for consumer health firms to orientate innovation around the goals, such as sleep, immunity and healthy aging, that consumers are already focused on.
HBW Insight - July 20, 2026

Supplement Industry Plants Longtime Use Flag As US Looks At Expanding Peptide Bulk Drugs List
FDA Pharmacy Compounding Advisory Committee on July 23-24 will review numerous peptides for addition to its bulk list for compounding by state-licensed physicians and pharmacists under FD&C Act Section 503A.
HBW Insight - July 20, 2026

The Generics Bulletin Podcast: Summer Conferences
Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.
Generics Bulletin - July 20, 2026

Only Two Generic Drug Makers At Administration’s Essential Medicine Production Meeting
The Trump Administration is developing incentives to reshore essential medicine production amid concerns China could disrupt US access to critical drugs and ingredients.
Generics Bulletin - July 20, 2026

Claims Open To Dip In The $533m Settlement Pot From US Price-Fixing Saga
Settlements from Apotex, Heritage, Sandoz, Sun Pharma, and Taro have been approved by a US federal court, releasing $533m to end-payers affected by an alleged decade-long generic drug price-fixing conspiracy.
Generics Bulletin - July 20, 2026

Caremark Settles FTC Case With Sweeping Drug-Pricing Reforms
CVS Caremark will overhaul rebates, patient cost-sharing, spread pricing and pharmacy reimbursement under an FTC settlement projected to deliver billions in savings.
Generics Bulletin - July 20, 2026

Hidden Cost Of Cancer Drug Shortages: Billions At Risk If Trial Protocols Unravel
Active US drug shortages rose for a third consecutive quarter, risking more clinical trial disruptions. In Vivo examines the likely fallout and explores solutions for cancer drug shortages as ASCO's chief medical officer warns of new drugs facing a potential threat of delays in approvals.
In Vivo - July 20, 2026